Franziska Lang

Franziska Lang

Auto-generated profile, based on publicly available information

Franziska Lang

TRON Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
FLFranziska Lang
Franziska Lang
PRPablo Riesgo-Ferreiro
Pablo Riesgo-Ferreiro
MLMartin Löwer
Martin Löwer
USUgur Sahin
Ugur Sahin
BSBarbara Schrörs
Barbara Schrörs
The detection and prediction of true neoantigens is of great importance for the field of cancer immunotherapy. Wesearched the literature for proposed neoantigen features and integrated them into a toolbox called NEOantigen Feature toolbOX (NeoFox). NeoFox is an easy-to-use Python package that enables the annotation of neoantigen candidates with 16 neoantigen features. NeoFox is freely available as an open source Python package released under the GNU General Public License (GPL) v3 license at https://github.com/TRON-Bioinformatics/neofox. Supplementary data are available at Bioinformatics online.

1 January 2024 in Bioinformatics Advances
Verified
Journal Article
Open access
PDF file
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
MSMartin Suchan
Martin Suchan
AHAlina Henrich
Alina Henrich
CAChristian Albrecht
Christian Albrecht
JIJonas Ibn-Salem
Jonas Ibn-Salem
Neoantigens are promising targets for cancer immunotherapies and might arise from alternative splicing. However, detecting tumor-specific splicing is challenging because many non-canonical splice junctions identified in tumors also appear in healthy tissues. To increase tumor-specificity, we focused on splicing caused by somatic mutations as a source for neoantigen candidates in individual patients. We developed the tool splice2neo with multiple functionalities to integrate predicted splice effects from somatic mutations with splice junctions detected in tumor RNA-seq and to annotate the resulting transcript and peptide sequences. Additionally, we provide the tool EasyQuant for targeted RNA-seq read mapping to candidate splice junctions. Using a stringent detection rule, we predicted 1.7 splice junctions per patient as splice targets with a false discovery rate below 5% in a melanoma cohort. We confirmed tumor-specificity using independent, healthy tissue samples. Furthermore, using tumor-derived RNA, we confirmed individual exon-skipping events experimentally. Most target splice junctions encoded neoepitope candidates with predicted MHC-I or MHC-II binding. Compared to neoepitope candidates from non-synonymous point mutations, the splicing-derived MHC-I neoepitope candidates had lower self-similarity to corresponding wild-type peptides. In conclusion, we demonstrate that identifying mutation-derived, tumor-specific splice junctions can lead to additional neoantigen candidates to expand the target repertoire for cancer immunotherapies. The R package splice2neo and the python package EasyQuant are available at https://github.com/TRON-Bioinformatics/splice2neo and https://github.com/TRON-Bioinformatics/easyquant, respectively. Supplementary data are available at Bioinformatics Advances online.

22 September 2023 in iScience
Verified
Journal Article
Open access
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
BSBarbara Schrörs
Barbara Schrörs
DWDavid Weber
David Weber
SKStefan Kramer
Stefan Kramer
MLMartin Löwer
Martin Löwer
Previous studies showed that the neoantigen candidate load is an imperfect predictor of immune checkpoint blockade (ICB) efficacy. Further studies provided evidence that the response to ICB is also affected by the qualitative properties of a few or even single candidates, limiting the predictive power based on candidate quantity alone. Here, we predict ICB efficacy based on neoantigen candidates and their neoantigen features in the context of the mutation type, using Multiple-Instance Learning via Embedded Instance Selection (MILES). Multiple instance learning is a type of supervised machine learning that classifies labeled bags that are formed by a set of unlabeled instances. MILES performed better compared with neoantigen candidate load alone for low-abundant fusion genes in renal cell carcinoma. Our findings suggest that MILES is an appropriate method to predict the efficacy of ICB therapy based on neoantigen candidates without requiring direct T cell response information.

6 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
BSBarbara Schrörs
Barbara Schrörs
DWDavid Weber
David Weber
SKStefan Kramer
Stefan Kramer
MLMartin Löwer
Martin Löwer
A successful response to immune checkpoint blockade treatment (ICB) depends on the functional re-invigoration of neoantigen-specific T cells and their anti-tumoral activity. Previous studies showed that the patient’s neoantigen candidate load is an imperfect predictor of the response to ICB. Further studies provided evidence that the overall response to ICB is also affected by the qualitative properties of a few or even single candidates, limiting the predictive power based on candidate quantity alone. To our knowledge, this is the first study to predict the response to ICB therapy based on qualitative neoantigen candidate profiles in the context of the mutation type, using a multiple instance learning approach. Multiple instance learning is a special branch of machine learning which classifies labelled bags that are formed by a set of unlabeled instances. The multiple instance learning approach performed systematically better than random guessing and was independent of the neoantigen candidate load. Qualitative modeling performed better in comparison to the quantitative approach, in particular for modelling low-abundant fusion genes. Our findings suggest that multiple instance learning is an appropriate method to predict immunotherapy efficacy based on qualitative neoantigen candidate profiles without relying on direct T-cell response information and provide a foundation for future developments in the field.

29 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
MSMartin Suchan
Martin Suchan
AHAlina Henrich
Alina Henrich
CAChristian Albrecht
Christian Albrecht
JIJonas Ibn-Salem
Jonas Ibn-Salem
Splicing is dysregulated in many tumors and may result in tumor-specific transcripts that can encode neoantigens, which are promising targets for cancer immunotherapy. Detecting tumor-specific splicing is challenging because many non-canonical splice junctions identified in tumor transcriptomes also appear in healthy tissues. Here, we developed splice2neo to integrate the predicted splice effects from somatic mutations with splice junctions detected in tumor RNA-seq for individual cancer patients. Splice2neo excludes splice junctions from healthy tissue samples, annotates resulting transcript and peptide sequences, and provides targeted re-quantification of supporting RNA-seq reads. We developed a stringent detection rule to predict splice junctions as mutation-derived targets and identified 1.7 target splice junctions per tumor with a false discovery rate below 5% in a melanoma cohort. We confirmed tumor-specificity using independent, healthy tissue samples. Furthermore, using tumor-derived RNA, we confirmed individual exon skipping events experimentally. Most target splice junctions encoded neoepitope candidates with predicted MHC-I or MHC-II binding. Compared to neoepitope candidates derived from non-synonymous point mutations, the splicing-derived MHC-I neoepitope candidates had a lower self-similarity to corresponding wild-type peptides. In conclusion, we demonstrate that identifying mutation-derived and tumor-specific splice junctions can lead to additional neoantigen candidates to expand the target repertoire for cancer immunotherapies. Key Points: splice2neo is a versatile tool for identifying and analyzing of splice junctions as a source of neoantigen candidates We identified mutation-retrieved splice junctions supported by RNA-seq in melanoma samples The predicted target splice junctions exhibited a strong tumor-specificity as they were absent in healthy tissues. Target splice junctions often lead to frame-shift peptides and encode promising neoantigen candidates

3 July 2026 in bioRxiv
Verified
Preprint
Open access
JHJohannes Hausmann
Johannes Hausmann
FLFranziska Lang
Franziska Lang
ÖMÖzlem Muslu
Özlem Muslu
LKLuis Kress
Luis Kress
JLJonathan J M Landry
Jonathan J M Landry
JIJonas Ibn-Salem
Jonas Ibn-Salem
Individualized cancer immunotherapies rely on tumor-specific T-cell antigens, often predicted from somatic mutations as neoantigens. For tumors with low mutational burden, mRNA transcript variants, including gene fusions and novel splice junctions, can serve as important alternative targets. A main challenge in their identification from tumor RNA-seq is to confirm that their expression is tumor-restricted. Although large public collections of healthy-tissue RNA-seq exist, verifying tumor-specific expression requires computationally expensive re-analysis of these data for every novel candi-date. To address this, we benchmarked nine k-mer indexing algorithms and devel-oped k4neo, which leverages k-mer indexing of raw RNA-seq reads to compute the tumor specificity of any transcript variant. This mapping-free and transcript-class ag-nostic approach screens any candidate sequence against 18,960 samples across 51 healthy tissue types. We confirmed k4neo's detection accuracy with qRT-PCR and showed that k4neo accurately classifies somatic and germline variants, gene fusions, and isoforms by tumor specificity. Applied to nine tumor cohorts, it nominated a medi-an of 4-80 tumor-specific splice junctions per patient, including recurrent, long-read-validated novel antigen candidates. Together, k4neo enables efficient access to large-scale sequencing cohorts and accurately computes tumor specificity for any in-put transcript sequence, thereby expanding the repertoire of individual and shared cancer antigen targets.